# Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years

> **NCT00290329** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 249 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Mencevax ACWY

## Key facts

- **NCT ID:** NCT00290329
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-14
- **Primary completion:** 2006-10-01
- **Final completion:** 2006-10-17
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290329, "Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00290329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*